Table 2 Correlations between Spry2 expression and clinicopathologic parameters of pancreatic cancer patients

From: miR-21 promotes EGF-induced pancreatic cancer cell proliferation by targeting Spry2

Parameters

No.

Spry2 expression

χ 2

P

(n = 63)

high (n = 21)

low (n = 42)

Gender

   

2.624

0.105

 Male

36

15

21

  

 Female

27

6

21

  

Age (years)

 ≤60

24

8

16

0.000

1.000

 >60

39

13

26

  

Tumor location

 Head

42

12

30

1.286

0.257

 Body/tail

21

9

12

  

 Tumor size (cm)

   

0.394

0.530

 ≤3

15

6

9

  

 >3

48

15

33

  

Pathologic grade

 I-II*

41

18

23

4.618

0.032

 III

22

3

19

  

T stage

 T1-T2*

22

11

11

4.226

0.040

 T3

41

10

31

  

N stage

 N0*

37

17

20

5.116

0.024

 N1

26

4

22

  

AJCC stage

 0-IIA**

36

17

19

7.292

0.007

 IIB-IV

27

4

23

  

Perineural invasion

   

1.167

0.280

 Absent

27

7

20

  

 Present

36

14

22

  

Vascular invasion

   

0.459

0.498

 Absent

48

15

34

  

 Present

15

6

9

  
  1. *P <0.05; **P < 0.01
Back to article page